Clinical trials: Bronchodilation
Paradoxical Fall in Maximum Expiratory Flows
Search of a Paradoxical Fall in Maximum Expiratory Flow After Bronchodilation in Healthy Subjects
There exists a physiological limitation of the expiratory flows because of the physical properties of the bronchial tree (flexible bronchial walls in a complex architecture subjected to variations of pressure and volume).
- Trial name
- VACUVOL (NCT03062904)
- Testing
- Inhaled Bronchodilators +/- Inhaled Methacholine
- Where
- France
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Chronic Obstructive Pulmonary Disease, Cardiovascular Disease
Interaction in Chronic Obstructive Pulmonary Disease Experiment
The final purpose of this study is to determine whether bronchodilation and cigarette smoking in Chronic Obstructive Pulmonary Disease (COPD) patients interact, resulting in an increase of cardiovascular disease.
- Conditions
- Chronic Obstructive Pulmonary Disease, Cardiovascular Disease, Smoking, Bronchodilation
- Trial name
- ICE (NCT00981851)
- Testing
- Tiotropium (Spiriva) + Salbutamol (Ventolin)
- Where
- 2 sites in Netherlands
- Volunteers
- 40 people
- Sponsor
- Radboud University Medical Center
Chronic Obstructive Pulmonary Disease
AMPLIFY - D6571C00001 Duaklir USA Phase III Study
This is a multiple dose, randomized, parallel, double-blind, double-dummy, multicenter and multinational Phase III study to determine the efficacy and safety of Aclidinium bromide 400μg/Formoterol Fumarate (AB/FF) 12 μg compared…
- Trial name
- NCT02796677
- Testing
- Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg), Aclidinium bromide 400 μg (AB 400 μg), Formoterol fumarate 12 μg (FF 12 μg)
- Where
- 163 sites in United States, Bulgaria and 8 more
- Volunteers
- 1,595 people
- Sponsor
- AstraZeneca
COPD
Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPD
The study investigates the effect of 3 days of twice daily treatment of two different doses of RPL554 (a phosphodiesterase [PDE]3/4 inhibitor) or placebo, each administered in addition to once daily tiotropium/olodaterol…
- Trial name
- NCT03673670
- Testing
- RPL554 Suspension, Tiotropium/olodaterol (Respimat)
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 79 people
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Mild Chronic Obstructive Pulmonary Disease, Respiratory Symptoms
GOLD Stage I Chronic Obstructive Pulmonary Disease (COPD)
Recently integrated in clinical practice, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification states that a mild (stage I) chronic obstructive pulmonary disease (COPD) is present, in a smoker, when…
- Conditions
- Mild Chronic Obstructive Pulmonary Disease, Respiratory Symptoms, Physical Activity
- Trial name
- GOLD (NCT01360788)
- Where
- Canada
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Laval University
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease
This study assessed the efficacy and safety of indacaterol (150 µg once daily [od]) when combined with tiotropium (18 µg od) versus tiotropium (18 µg od) treatment alone in patients with chronic obstructive pulmonary disease…
- Trial name
- INTRUST1 (NCT00846586)
- Testing
- Indacaterol 150 μg, Tiotropium 18 μg
- Where
- 137 sites in United States, Argentina and 10 more
- Volunteers
- 1,134 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Single Dose Bronchodilatory Study in Asthma
Study to evaluate the bronchodilator effects of Zyflo CR in patients with chronic stable asthma.
- Trial name
- NCT01805687
- Testing
- Zileuton extended release
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Cornerstone Therapeutics Inc.
Chronic Obstructive Pulmonary Disease
Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to further figure out differences of glycopyrronium bromide compared to tiotropium in early bronchodilation measured by a comprehensive assessment of lung function that includes hyperinflation and…
- Trial name
- FAST (NCT01922271)
- Testing
- NVA237, Tiotropium, Salbutamol
- Where
- 14 sites in Germany
- Volunteers
- 152 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
OTIVACTO Spain Non Interventional Study
This is a self-controlled study design enrolling consented COPD patients who will be treated with Spiolto® Respimat® according to the approved SmPC.
- Trial name
- NCT02927795
- Where
- 79 sites in Spain
- Volunteers
- 257 people
- Sponsor
- Boehringer Ingelheim
Allergic Rhinitis, Asthma
Study of Bronchodilation Effects of Cetirizine
Primary Objective : To compare the acute bronchodilatory effects of cetirizine 10 mg tablet and nebulized levalbuterol using impulse oscillometry technique in asthmatic subjects aged 18 to 65 years old who have allergic rhinitis…
- Trial name
- NCT01781507
- Testing
- Cetirizine
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- California Allergy and Asthma Medical Group, Inc.
COPD
Dose Ranging Study of RPL554 in Chronic Obstructive Pulmonary Disease (COPD) Patients
The study investigates the effect of 4 weeks of twice daily treatment of four different doses of RPL554 (a phosphodiesterase [PDE]3/4 inhibitor) or placebo in patients with moderate to severe chronic obstructive pulmonary disease…
- Trial name
- NCT03443414
- Testing
- RPL554 suspension
- Where
- 49 sites in Bulgaria, Czechia and 4 more
- Volunteers
- 405 people
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Pulmonary Disease, Chronic Obstructive
OTIVACTO Regional Center Vienna (RCV) Non-Interventional Study (NIS)
Real-world data on the effects of a fixed-dose combination Long-acting beta agonists + long-acting antimuscarinic agent (LABA+LAMA) therapy with tiotropium and olodaterol administered in a single device, in COPD patients who need…
- Trial name
- NCT02719639
- Where
- 9 sites in Austria, Czechia and 7 more
- Volunteers
- 7,443 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Assessment of Physical Functioning and Handling of Spiolto® Respimat® in Patients With Chronic Obstructive Pulmonary Disease (COPD) Requiring Long-acting Dual Bronchodilation in Routine Clinical Practice
The primary objective of the study is to measure changes in physical functioning - serving as a surrogate for physical activity and exercise capacity - in COPD patients being treated with Spiolto® Respimat® after approximately 6…
- Trial name
- NCT02675517
- Testing
- Spiolto Respimat
- Where
- Germany
- Volunteers
- 1,737 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Sensitivity of New Exercise Tests in Chronic Obstructive Pulmonary Disease (COPD)
This study was designed to test the following hypothesis: The 3-min constant rate step test and the 3-min constant rate shuttle walk test will be sensitive to detect improvement in exertional dyspnea following acute…
- Trial name
- NCT00807534
- Testing
- ipratropium bromide, constant rate step test, constant rate shuttle walk test
- Where
- 2 sites in Canada
- Volunteers
- 44 people
- Sponsor
- Laval University
Pulmonary Disease, Chronic Obstructive
Effects of Acute Long-acting Bronchodilation on Oxygenation and Peripheral Ventilation in COPD
The goal of this clinical trial was to compare the action of long-acting ß2-agonists (LABA-olodaterol) and muscarinic antagonists (LAMA-tiotropium) on tissue oxygenation in COPD considering their impact on proximal and peripheral…
- Trial name
- NCT05927155
- Testing
- LABA, LAMA
- Where
- Belgium
- Volunteers
- 30 people
- Sponsor
- Erasme University Hospital
Emphysema, COPD
Bronchoreversibility and Radiologic Morphology of Emphysema
To assess response to bronchodilation with tiotropium plus salbutamol in patients with severe emphysema and analyze relationships between bronchoreversibility response and semiquantitative computed-tomography based emphysema…
- Trial name
- NCT02008162
- Testing
- Bronchodilators
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- University of Rome Tor Vergata
COPD, CT
Effects of Bronchodilation on Computed Tomography (CT) Parameters Reflecting Airways Remodelling, and Pulmonary Emphysema Extent.
CT studies considering bronchial dimensions in chronic obstructive pulmonary disease (COPD) were conducted without control of bronchodilation.
- Conditions
- COPD, CT, Bronchodilation
- Trial name
- NCT01142531
- Testing
- Chest CT scan
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- Erasme University Hospital
Chronic Obstructive Pulmonary Disease Moderate, Chronic Obstructive Pulmonary Disease Severe
Respiratory and Cardiovascular Alterations in Patients With Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease (COPD) is a lung condition characterized by chronic respiratory symptoms (dyspnoea, cough, sputum production and/or exacerbations) due to abnormalities of the airways (e.g.
- Conditions
- Chronic Obstructive Pulmonary Disease Moderate, Chronic Obstructive Pulmonary Disease Severe, Cardiovascular Diseases, Quality of Life
- Trial name
- NCT06072690
- Where
- Lithuania
- Volunteers
- 80 people
- Sponsor
- Lithuanian University of Health Sciences
COPD, Chronic Obstructive Pulmonary Disease (COPD)
Phase 2b Efficacy and Safety Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients
This is a phase 2b, randomized, double-blind, placebo-controlled, dose-ranging,14-day dosing, 2-period crossover study in participants with chronic obstructive pulmonary disease (COPD).
- Conditions
- COPD, Chronic Obstructive Pulmonary Disease (COPD), Lung Disease Chronic, Lung Diseases, Obstructive
- Trial name
- AERODUO-2 (NCT07896252)
- Testing
- AERO-001, AERO-002, AERO-007
- Volunteers
- 64 people
- Sponsor
- AeroRx Therapeutics Inc.
COPD
Phase 1/Phase 2a Study of AERO-007 Inhalation Solution, a Nebulized LABA/LAMA Combination for Maintenance Treatment of COPD
This is a phase 1/phase 2a, single dose, crossover study conducted in two parts. Part 1: Phase 1, open-label, 4-period crossover study in 8 healthy subjects to determine the optimal dose of AERO-001 and AERO-002, the active…
- Trial name
- NCT06841640
- Testing
- AERO-001, AERO-002, AERO-007
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AeroRx Therapeutics Inc.